Vaxil Bio Ltd.

Equities

VXL

CA92243L1076

Biotechnology & Medical Research

Market Closed - Toronto S.E. Other stock markets 03:10:23 2024-04-26 pm EDT			5-day change	1st Jan Change
0.015 ^CAD	+50.00%		0.00%	-40.00%

Mar. 04	Copper Bullet Mines Inc. cancelled the acquisition of Vaxil Bio Ltd. in a reverse merger transaction.	CI
Jan. 10	Vaxil Bio Entered Into Letter Of Intent With Copper Bullet Mines In Respect Of A Proposed Reverse Takeover	MT

Vaxil Bio Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022

November 21, 2022 at 05:04 pm EST

Vaxil Bio Ltd. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported net loss was CAD 0.139 million compared to CAD 0.239 million a year ago.
For the nine months, net loss was CAD 0.411 million compared to CAD 0.706 million a year ago.

Latest news about Vaxil Bio Ltd.

Copper Bullet Mines Inc. cancelled the acquisition of Vaxil Bio Ltd. in a reverse merger transaction.	Mar. 03	CI
Vaxil Bio Entered Into Letter Of Intent With Copper Bullet Mines In Respect Of A Proposed Reverse Takeover	Jan. 10	MT
Copper Bullet Mines Inc. entered into a non-binding letter of intent to acquire Vaxil Bio Ltd. for CAD 15.8 million in a reverse merger transaction.	Jan. 09	CI
Vaxil Bio Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 12	CI
Vaxil Bio Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-27	CI
Vaxil Bio Ltd. Announces CFO Changes	23-08-02	CI
Vaxil Bio Ltd. Announces CEO Changes	23-08-02	CI
Vaxil Bio Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-29	CI
Vaxil Bio Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-27	CI
Vaxil Bio Ltd. Auditor Raises 'Going Concern' Doubt	23-04-26	CI
Vaxil Bio Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-21	CI
Vaxil Bio Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-25	CI
Vaxil Bio Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-26	CI
Vaxil Bio Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-29	CI
Vaxil Bio Ltd. Auditor Raises 'Going Concern' Doubt	22-04-28	CI
Vaxil Bio Provides Update on Research Activities	22-03-07	MT
Vaxil Bio Provides Final Results on Research With Ben-Gurion University	22-01-04	MT
Vaxil Bio Ltd. Provides an Update on the Results of in Vivo Efficacy Study for Licensed P-Esbp-DOX	22-01-04	CI
Vaxil Bio Ltd. Announces Resignation of David Goren as Director	21-12-13	CI
Vaxil Bio Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-25	CI
Vaxil Bio Will Not Move Ahead with the Acquisition of Short Wave Pharma Following Due Diligence	21-11-11	MT
Vaxil Bio Ltd. cancelled the acquisition of Short Wave Pharma Inc.	21-11-10	CI
Vaxil Bio : Reports Letter of Intent to Buy 100% Interest in Short Wave Pharma; Up 10%	21-10-14	MT
Vaxil Bio : Reports Letter of Intent to Buy 100% Interest in Short Wave Pharma	21-10-14	MT
Vaxil Bio Ltd. entered into a non-binding letter of agreement to acquire Short Wave Pharma Inc. for CAD 2.5 million.	21-10-13	CI

Chart Vaxil Bio Ltd.

Duration

Period

More charts

Company Profile

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Companyâs most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.

Sector

Biotechnology & Medical Research

Calendar

2024-05-26 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VAXIL BIO LTD.	-40.00%	1.5M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs